The inhibition of AR, which is the rate-limiting enzyme of the polyol pathway, is considered effective for the treatment of DN, and epalrestat is the only oral drug that is currently approved for such use Japan [12]. The gene discussed is AR; the disease is liver dysplastic nodule.